FILING ANALYSIS · THURSDAY, NOVEMBER 12
KIORA PHARMACEUTICALS INC KPRX — 8-K: Results of Operations and Financial Condition
neutral
Kiora Pharmaceuticals has in-licensed a late-stage oral neuroprotective calpain inhibitor, KIO-401, with existing Phase 2 and Phase 3 studies conducted in Japan, and is planning a multinational registration clinical trial, which could be a significant development for the company's pipeline. The company ended the quarter with approximately $16.3 million in cash and short-term investments, plus $2.2
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →